Title

Translating sequencing-based tumour profiling and prediction models to the clinic

Speaker:

Dr Mattias Rantalainen, Karolinska Institutet

Date & Time:

Thursday, 16 April 2015, 14:00

Location: 
Old Road Campus Research Building, Room 71abc, Headington OX3 7DQ
Host: 
Cancer Bioinformatics Seminar Series

DNA and RNA sequencing are now standard tools in cancer research but are not yet widely implemented in the clinical setting. Translation of sequencing-based molecular phenotyping to the clinic holds the promise to provide a quantitative and more detailed basis for diagnosis and prognosis compared to conventional pathology, and thus lead to improved patient outcomes.

In this talk I will present results from the ClinSeq (Clinical Sequencing of Cancer in Sweden) breast cancer study. ClinSeq aims to develop and evaluate infrastructure, bioinformatic methods and statistical models to bring sequencing-based cancer diagnostics to the clinic. Using multivariate prediction modelling we assess to what extent DNA and RNA sequencing-based molecular profiling of primary breast cancer tumours can replace, and potentially augment, current routine pathology, including immunohistochemical markers and histological grade. Our results, based on a retrospective study including DNA and RNA sequencing of ~300 primary breast cancer tumours, indicate a high degree of concordance between conventional markers and predictions from models based on sequencing data, while also providing additional treatment relevant information. Around 8% of cases are reclassified by sequencing-based models and these cases also have an increased probability of reclassification under pathological re-examination.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.